Autoimmune Rheumatic Disease Patients Face Higher Long COVID Risk
Patients diagnosed with autoimmune rheumatic diseases face a substantially elevated risk of developing long COVID compared to individuals without these conditions, according to a retrospective study published in the journal Arthritis & Rheumatology.
The analysis revealed that long COVID manifested in 2.8 percent of patients with autoimmune inflammatory arthritis, contrasted against a 1.5 percent incidence rate within a control group of 187,106 non-affected patients. Through a multivariable analysis, researchers established that having an autoimmune inflammatory arthritis condition correlates with a 1.56 adjusted hazard ratio for developing the persistent syndrome.
Clinical Factors Elevating Long COVID Susceptibility
Beyond the underlying rheumatic diagnosis itself, several specific clinical variables compounded the likelihood of prolonged post-viral symptoms. Severity of acute COVID-19 illness, pre-existing lung disease, and obesity all emerged as notable risk factors within this patient cohort. Specific pharmacological exposures—namely treatments involving rituximab or glucocorticoids—heightened vulnerability to long COVID among individuals managing autoimmune conditions.
The study also identified a distinct statistical association between Sjögren’s syndrome and an increased probability of prolonged symptoms. The research team emphasized that these findings show an urgent clinical necessity for close patient monitoring, deeper investigation into underlying biological mechanisms, and targeted prevention strategies tailored to autoimmune populations.
Frequently Asked Questions About Autoimmune Disease and Long COVID
Which specific medications were linked to higher vulnerability?
The study identified patient exposure to rituximab or glucocorticoids as factors associated with an increased risk of developing long COVID among individuals with autoimmune inflammatory arthritis.
How much higher was the incidence rate in rheumatic patients versus the control group?
Long COVID occurred in 2.8 percent of autoimmune inflammatory arthritis patients compared to 1.5 percent of individuals in the 187,106-person control group.
Worth a look
- Lung Cancer Radiotherapy: New Study Data and European Guidelines
- Hamilton Health Sciences to Eliminate Over 400 Positions Amid $150M Deficit
- 'American Covid' Isn't New, and So Far Its Autumn Is Smaller Than 2025's (daybreakwire.com)
- Study: Moderate-strength tea may lower vascular disease risk by 11% (archyworldys.com)